Tesamorelin Complete Guide: GHRH Analogue for Visceral Fat, Mechanism, Dosing, and Safety (2026)

What Is Tesamorelin? The GHRH Analogue With FDA-Approved Evidence

Tesamorelin is a stabilised synthetic analogue of growth hormone-releasing hormone (GHRH), engineered to stimulate the pituitary gland's own pulsatile growth hormone secretion. Unlike exogenous HGH, it works with your body's feedback systems. It holds active FDA approval as Egrifta for HIV-associated lipodystrophy and carries the strongest clinical evidence base of any GHRH peptide currently in use.

If you are researching tesamorelin, you are looking at a compound that sits in a different category to most research peptides. It has been through two large Phase III randomised controlled trials, a pooled analysis of 806 patients, and a 2025 label update from the FDA. That does not make it a free pass, but it does mean the evidence base is qualitatively different to what underpins sermorelin or CJC-1295.

This guide covers everything a serious researcher or clinically supervised patient needs to understand before engaging with tesamorelin: what it is, how it works, what the trials actually show (and where they fall short), how it compares to other GH-axis peptides, dosing fundamentals, safety profile, legal status, and sourcing standards. Each section links to the dedicated spoke articles where depth matters.

Affiliate disclosure: Underground Biohacking may receive a commission if you purchase through links on this page. This does not affect editorial independence. Vendor recommendations are based on third-party testing standards. See our recommended sources page for the full vetting criteria.

Mechanism: How Tesamorelin Stimulates Growth Hormone

Tesamorelin binds to GHRH receptors on somatotroph cells in the anterior pituitary and activates the Gs-protein/cAMP signalling cascade, triggering endogenous pulsatile GH release. The pituitary's own feedback loop stays intact. This preserves the natural rhythm of GH secretion rather than bypassing it the way exogenous HGH does.

The compound is a 44-amino-acid synthetic analogue of endogenous GHRH, modified at the N-terminus with a trans-3-hexenoic acid group. That modification stabilises the molecule against enzymatic degradation by dipeptidyl peptidase IV, extending its half-life and improving bioavailability compared to native GHRH (NCBI Bookshelf 2018).

The downstream sequence is straightforward: tesamorelin binds the GHRH receptor, adenylate cyclase is activated, intracellular cAMP rises, and GH is synthesised and released in pulses. The liver responds by producing insulin-like growth factor-1 (IGF-1). IGF-1 then mediates the metabolic effects, including enhanced lipolysis in visceral adipose tissue (NCBI Bookshelf 2018).

Critically, because the pituitary's somatostatin-mediated negative feedback remains functional, you get physiological GH pulses rather than the continuous supraphysiological GH levels associated with direct HGH injection. In healthy men receiving 2 mg SC daily for two weeks, tesamorelin increased mean overnight GH (p=0.004), GH pulse amplitude (p=0.001), and IGF-1 by 181 µg/L (p<0.0001), while insulin-stimulated glucose uptake remained unaffected (p=0.61) (Falutz 2010).

GHRH-R is also expressed in extrapituitary tissues, suggesting potential autocrine and paracrine roles in metabolism and tissue regulation beyond the pituitary axis (Havt 2023).

The Clinical Evidence Base: What the Trials Actually Show

Tesamorelin has the most substantial randomised controlled trial evidence of any GHRH analogue. Multiple Phase III trials in HIV-infected patients demonstrate 15 to 18% visceral adipose tissue reduction over 26 weeks versus placebo. That evidence is strong. The off-label evidence in general populations is thinner and should not be overstated.

Approved indication: HIV-associated lipodystrophy

Two pivotal Phase III trials enrolled a combined 806 HIV-infected patients with excess abdominal fat. Tesamorelin 2 mg SC daily reduced visceral adipose tissue by 15.4% versus placebo at 26 weeks (p<0.001), with concurrent reductions in fasting triglycerides and liver fat (Falutz 2010). A separate 404-patient RCT confirmed an 18% VAT reduction with improved body image distress and no significant perturbation of glucose metabolism (Falutz 2010b).

A 2024 meta-analysis of five RCTs confirmed the picture: tesamorelin produced a mean difference of -27.71 cm² in visceral adipose tissue (p<0.001), increased lean body mass, and elevated IGF-1, with no serious adverse events or glucose perturbation across the pooled dataset (Oraei 2024).

An important nuance: tesamorelin reduces visceral (deep, metabolically active) fat selectively. Subcutaneous fat remains largely unchanged (Falutz 2010). For someone concerned about surface body fat, the compound is not the right tool. For visceral adiposity, it is the most evidence-backed option in the peptide space.

Off-label applications: what the evidence does and does not support

The off-label interest in tesamorelin centres on visceral fat reduction and body composition in non-HIV adults, non-alcoholic fatty liver disease, and general GH-axis optimisation. The mechanistic rationale is sound. But the randomised trial evidence in non-HIV populations is limited. A 12-week trial in 53 type 2 diabetic patients showed no significant difference in insulin response, fasting glucose, or HbA1c versus placebo, which is reassuring for glucose safety at physiological doses (Yuen 2017). Ongoing trials are evaluating tesamorelin for liver fat in HIV-positive patients with NAFLD (Stanley 2021).

The honest position: the mechanism supports broader application, the safety data is reassuring at physiological doses, but anyone extrapolating the Phase III efficacy data to healthy middle-aged men is making an inference, not citing a trial. State that clearly when discussing off-label use.

Primary Use Cases

Tesamorelin's primary approved use is visceral abdominal fat reduction in HIV-associated lipodystrophy. Off-label, clinicians and researchers use it for general visceral fat reduction, GH and IGF-1 optimisation, body composition improvement, and potential metabolic and hepatic benefits in adults with elevated visceral adiposity.

• Visceral fat reduction: The compound's strongest evidence. Targets deep abdominal fat specifically without significant effect on subcutaneous fat.
• GH and IGF-1 axis optimisation: Raises endogenous GH pulsatility and IGF-1 within physiological ranges without suppressing the HPG axis or requiring exogenous HGH.
• Body composition: Meta-analysis data shows concurrent lean body mass increase alongside VAT reduction, suggesting a dual recomposition effect.
• Hepatic metabolic benefit: VAT reduction correlates with improved liver transaminases in patients with baseline elevation (Falutz 2017), and the compound is under investigation for NAFLD.
• Immune modulation (emerging): A 12-month RCT found tesamorelin decreased markers of cytotoxic T-cell and monocyte activation, suggesting effects beyond metabolism (Stanley 2021).

Dosing: What the Evidence Supports

FDA-approved dosing is 2 mg subcutaneous once daily (Egrifta SV formulation) or 1.28 mg SC once daily (Egrifta WR, the 2025 weekly-reconstitution formulation). Both are administered via subcutaneous injection into the abdomen with site rotation. Off-label protocols vary; dose adjustments are typically guided by IGF-1 response.

The two current FDA-approved formulations differ in reconstitution convenience rather than compound efficacy:

• Egrifta SV: 2 mg SC once daily. Daily reconstitution. The original clinical trial dose.
• Egrifta WR: 1.28 mg SC once daily. Weekly reconstitution convenience. Updated 2025 prescribing label (FDA 2025).

Injection site rotation within the abdominal region is mandatory. Avoid scar tissue, bruises, and the navel. Dose reductions to 1 mg daily have been used in trial settings when IGF-1 rises above the upper limit of the age-appropriate reference range.

Treatment duration in clinical trials ran from 26 to 52 weeks. Off-label protocols vary widely from 6-week loading phases to extended multi-month programmes. Long-term safety data beyond 52 weeks is not formally established (Stanley 2012).

For a detailed protocol breakdown, reconstitution method, IGF-1 monitoring schedule, and injection technique, see the dedicated tesamorelin dosage protocol guide.

Always work with a qualified clinician before making changes to your health protocol.

How Tesamorelin Compares to Other GH-Axis Peptides

Tesamorelin has a fundamentally different regulatory standing from every other GH-axis peptide: it holds active FDA approval backed by multiple Phase III RCTs. Sermorelin and CJC-1295 are GHRH analogues like tesamorelin but lack its trial evidence and FDA status. Ipamorelin works via a different receptor pathway altogether, making it mechanistically complementary rather than equivalent.

Tesamorelin vs Sermorelin

Both are GHRH analogues that stimulate pituitary GH release. Sermorelin is the truncated 1-29 fragment of endogenous GHRH. Tesamorelin is a full-length 44-amino-acid analogue with an N-terminal stabilising modification, making it more resistant to enzymatic degradation. Tesamorelin has a substantially stronger evidence base and regulatory standing. Sermorelin has a longer history of off-label clinical use and is more widely available from compounding pharmacies. See the dedicated tesamorelin vs sermorelin comparison for the full breakdown.

Tesamorelin vs CJC-1295

CJC-1295 is a long-acting GHRH analogue that binds albumin for extended half-life, allowing weekly rather than daily dosing. It lacks FDA approval and has no Phase III trial evidence. CJC-1295 is often combined with ipamorelin in off-label protocols. Tesamorelin's daily dosing preserves more physiological GH pulsatility than CJC-1295's extended blunting of the GH pulse pattern.

Tesamorelin vs Ipamorelin

Ipamorelin is a ghrelin receptor agonist (growth hormone secretagogue), not a GHRH analogue. It works through a different receptor system. Both ultimately increase GH output, but via distinct pathways that are complementary, which is why some clinicians combine them. Tesamorelin has stronger visceral fat trial data; ipamorelin is valued for its selective GH release with minimal effect on cortisol or prolactin. See the full tesamorelin vs ipamorelin comparison for mechanism and use-case differences.

Tesamorelin vs Exogenous HGH

This is the comparison that matters most for understanding why tesamorelin occupies its niche. Exogenous HGH delivers supraphysiological continuous GH, bypassing the pituitary and suppressing endogenous GH secretion over time. The risks of pharmacological HGH doses include insulin resistance, acromegalic changes, fluid retention, and potential carcinogenic implications from sustained IGF-1 elevation. Tesamorelin works upstream, prompting the pituitary to release GH in its natural pulsatile pattern. The feedback loop remains intact. In healthy men, tesamorelin at 2 mg daily preserved insulin-stimulated glucose uptake while significantly raising IGF-1 (Falutz 2010).

Side Effects and Safety Profile

Tesamorelin's most common side effects are injection-site reactions and arthralgia, both mild and infrequent. The compound does not appear to impair glucose metabolism at physiological doses, though individuals with diabetes or pre-diabetes require monitoring. Roughly half of patients develop anti-tesamorelin antibodies, and long-term safety beyond 52 weeks has not been formally established.

Common adverse events

• Injection-site reactions (erythema, pruritus, pain, urticaria): 8 to 13% of treated patients versus 5 to 7% placebo. Generally mild, rarely causing discontinuation (Falutz 2011).
• Arthralgia (joint pain): 6 to 13% versus 4 to 9% placebo. Consistent with GH-mediated connective tissue stimulation, a recognised class effect across GH-axis therapies (Falutz 2011).
• Peripheral oedema and myalgia: Reported in trials; consistent with fluid retention from GH-mediated sodium retention. Usually transient.

Glucose and insulin sensitivity

Growth hormone is a counter-regulatory hormone that can raise blood glucose in pharmacological doses. At physiological doses via tesamorelin, the clinical evidence is reassuring. In healthy men, insulin-stimulated glucose uptake was preserved (p=0.61) despite significant IGF-1 elevation (Falutz 2010). In type 2 diabetic patients specifically, 12 weeks of tesamorelin 1 to 2 mg produced no significant difference in insulin response, fasting glucose, or HbA1c versus placebo (Yuen 2017). Nevertheless, monitoring baseline and periodic fasting glucose and HbA1c is standard practice and appropriate for any GH-axis therapy.

Antibody development

Approximately 49.5% of patients develop anti-tesamorelin IgG antibodies after 26 weeks, with approximately 60% cross-reactivity to endogenous GHRH. In cases of hypersensitivity, antibodies were detected in 85.2% of affected patients. Most antibody-positive patients do not experience clinically meaningful effects on efficacy or safety, but hypersensitivity reactions are possible and monitoring is warranted (Falutz 2011).

Reversibility

Tesamorelin's effects are reversible upon discontinuation. GH, IGF-1, and any modest fasting glucose changes normalise within weeks. Pituitary responsiveness to endogenous GHRH recovers (Falutz 2010b). This is a meaningful distinction from long-term exogenous HGH use, where pituitary suppression can be more persistent.

Theoretical longer-term considerations

Long-term safety beyond 52 weeks has not been formally established in randomised trials (Stanley 2012). IGF-1 is a mitogenic growth factor, and sustained elevation carries a theoretical concern for tumour promotion, particularly in individuals with prior malignancy. Active malignancy is an absolute contraindication. Regular IGF-1 monitoring is essential during use.

Contraindications: Who Should Not Use Tesamorelin

Tesamorelin is absolutely contraindicated in active malignancy, pregnancy, pituitary tumours, and recent pituitary surgery. Relative caution applies in patients with diabetes, pre-diabetes, cardiovascular risk, or a prior history of malignancy. These are not optional disclaimers; they reflect the FDA prescribing label and the pharmacology of GH-axis stimulation.

Per the 2025 FDA prescribing information, tesamorelin is contraindicated in:

• Patients with active malignancy (ongoing or recently treated)
• Pregnancy
• Patients with pituitary gland tumours
• Patients who have undergone pituitary surgery or have other pituitary gland disorders (FDA 2025)

Relative contraindications and caution populations:

• Type 2 diabetes or pre-diabetes (monitor glucose and HbA1c; evidence is reassuring at physiological doses but monitoring is non-negotiable)
• Prior malignancy history (theoretical IGF-1 mitogenic risk)
• Cardiovascular disease (elevated GH and IGF-1 have complex cardiovascular effects)
• Patients already receiving pharmacological GH therapy

Always work with a qualified clinician before making changes to your health protocol.

Legal and Regulatory Status

Tesamorelin holds active FDA approval as Egrifta (prescription medication) for HIV-associated lipodystrophy in adults, making it one of the few peptides with a clear legal prescription pathway in the United States. Research-grade tesamorelin sold by unregulated peptide vendors is labelled for research use only and is not approved for human consumption.

The regulatory timeline matters:

• November 2010: FDA approval of original Egrifta (2 mg formulation) for HIV lipodystrophy (Wierzbicki 2010).
• 2025: Updated label for Egrifta WR (1.28 mg weekly-reconstitution formulation), maintaining the same HIV lipodystrophy indication (FDA 2025).

For the FDA-approved indication, tesamorelin is legal when prescribed by a licensed clinician. Off-label use in non-HIV patients is not FDA-approved but falls within legal medical discretion in the United States when prescribed. Grey-market research-grade tesamorelin from unregulated peptide suppliers operates in a different legal category entirely: these products are sold labelled for research use only and are not legally approved for human administration.

The regulatory status is a meaningful differentiator. Unlike sermorelin (compounded, no current FDA approval for any indication) or CJC-1295 (no FDA approval), tesamorelin has a clear, active FDA approval pathway for the right patient population. That matters for quality assurance, prescribing legitimacy, and long-term safety monitoring frameworks.

Sourcing and Quality Verification

Quality verification is non-negotiable for any peptide used outside the prescription pharmaceutical pathway. For research-grade tesamorelin, mandatory standards include third-party certificate of analysis covering purity by HPLC, mass spectrometry confirmation of correct molecular weight, and endotoxin testing. Any supplier unable to provide current third-party COAs should be disqualified.

For the prescription route (Egrifta brand), the quality question is answered: pharmaceutical-grade manufacturing under FDA oversight. For research-grade tesamorelin from grey-market suppliers, the buyer bears all quality verification responsibility.

What to verify from any research peptide supplier:

• HPLC purity report: >98% purity is the minimum standard for a credible supplier
• Mass spectrometry confirmation: molecular weight must match tesamorelin (MW: 5135.9 Da for the modified 44-amino-acid analogue)
• Endotoxin (LAL) testing certificate
• Independent (not in-house) third-party laboratory issuing the COA
• Batch-specific COA that matches the vial you receive

See our recommended sources page for the full supplier vetting criteria and current third-party-tested options.

References

• Falutz J, et al. (2010). Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension. J Acquir Immune Defic Syndr.
• Falutz J, et al. (2010). Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat: pooled analysis of two Phase 3 trials. J Acquir Immune Defic Syndr.
• Falutz J, et al. (2010). Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity in healthy men. J Clin Endocrinol Metab.
• NCBI Bookshelf (2018). Tesamorelin. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. NIH.
• FDA (2025). EGRIFTA WR (tesamorelin) Full Prescribing Information.
• Stanley TL, Grinspoon SK (2012). Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy. Expert Rev Endocrinol Metab.
• Havt A, et al. (2023). Signaling mechanism of growth hormone-releasing hormone receptor. Peptides.
• Oraei M, et al. (2024). Body composition, hepatic fat, metabolic, and safety outcomes of tesamorelin: a meta-analysis of randomized controlled trials. J Endocrinol Invest.
• Falutz J (2011). Spotlight on tesamorelin in HIV-associated lipodystrophy. Drug Des Devel Ther.
• Yuen KCJ, et al. (2017). Safety and metabolic effects of tesamorelin in patients with type 2 diabetes: a randomized, placebo-controlled trial. Diabetes Care.
• Stanley TL, et al. (2021). Growth hormone releasing hormone reduces circulating markers of immune activation in HIV infection with nonalcoholic fatty liver disease. EBioMedicine.
• Falutz J, et al. (2017). Visceral fat reduction with tesamorelin is associated with improved liver enzymes in HIV. AIDS.
• Wierzbicki AS (2010). FDA approves tesamorelin for HIV-related lipodystrophy. Curr Opin Investig Drugs.

This content is for educational purposes only. These compounds are intended for research use. Nothing here is medical advice. Always work with a qualified clinician before making changes to your health protocol.